SG11202000321PA - Cd38 modulating antibody - Google Patents
Cd38 modulating antibodyInfo
- Publication number
- SG11202000321PA SG11202000321PA SG11202000321PA SG11202000321PA SG11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA
- Authority
- SG
- Singapore
- Prior art keywords
- stevenage
- tusk
- catalyst
- international
- therapeutics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762546322P | 2017-08-16 | 2017-08-16 | |
US201762582666P | 2017-11-07 | 2017-11-07 | |
US201762582653P | 2017-11-07 | 2017-11-07 | |
PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
PCT/EP2018/072271 WO2019034752A1 (en) | 2017-08-16 | 2018-08-16 | CD38 MODULATOR ANTIBODY |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000321PA true SG11202000321PA (en) | 2020-02-27 |
Family
ID=65361804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000321PA SG11202000321PA (en) | 2017-08-16 | 2018-08-16 | Cd38 modulating antibody |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230089373A1 (ko) |
EP (1) | EP3668896A1 (ko) |
JP (1) | JP7224338B2 (ko) |
KR (1) | KR20200036860A (ko) |
CN (1) | CN111032693B (ko) |
AU (1) | AU2018316521A1 (ko) |
CA (1) | CA3073085A1 (ko) |
SG (1) | SG11202000321PA (ko) |
WO (1) | WO2019034752A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
EP1888647A2 (en) * | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
CA2773240C (en) | 2009-09-22 | 2015-11-10 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
CA3117920A1 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Libraries comprising segmental pools, and methods for their preparation and use |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
-
2018
- 2018-08-16 SG SG11202000321PA patent/SG11202000321PA/en unknown
- 2018-08-16 KR KR1020207003075A patent/KR20200036860A/ko not_active Application Discontinuation
- 2018-08-16 CN CN201880051748.0A patent/CN111032693B/zh active Active
- 2018-08-16 CA CA3073085A patent/CA3073085A1/en active Pending
- 2018-08-16 WO PCT/EP2018/072271 patent/WO2019034752A1/en unknown
- 2018-08-16 AU AU2018316521A patent/AU2018316521A1/en active Pending
- 2018-08-16 EP EP18753198.3A patent/EP3668896A1/en active Pending
- 2018-08-16 JP JP2020508326A patent/JP7224338B2/ja active Active
-
2022
- 2022-11-30 US US18/060,135 patent/US20230089373A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020531003A (ja) | 2020-11-05 |
EP3668896A1 (en) | 2020-06-24 |
KR20200036860A (ko) | 2020-04-07 |
CN111032693A (zh) | 2020-04-17 |
US20230089373A1 (en) | 2023-03-23 |
CN111032693B (zh) | 2023-09-26 |
JP7224338B2 (ja) | 2023-02-17 |
CA3073085A1 (en) | 2019-02-21 |
WO2019034752A1 (en) | 2019-02-21 |
AU2018316521A1 (en) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908578YA (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201806992VA (en) | Antibodies to tigit | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908994RA (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11202000484TA (en) | Cd38 antibody | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |